IMV - IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%

IMV (IMV) announces updated data from a Phase 2 clinical trial, DeCidE1, evaluating DPX-Survivac, combined with intermittent low-dose cyclophosphamide (chemo agent), in patients with recurrent advanced platinum-sensitive and platinum-resistant ovarian cancer.78.9% (n=15/19) of evaluable patients showed partial responses or stable cancer. Clinical benefits over six months were observed in 36.8% (n=7/19) while 26.3% (n=5/19) experienced clinical benefits for about a year. 10.5% (n=2/19) are still benefiting from treatment.Median progression-free survival ((PFS)) was 4.5 months. Overall survival ((OS)) rate at month 12 was 66.1%.On the safety front, DPX-Survivac was well-tolerated. The majority of treatment-related adverse events were mild, mostly injection site reactions.DPX-Survivac is an T cell-activating immunotherapy that targets a cancer stem cell antigen called survivin. The company says survivin is a high value target because it has the capacity to disrupt cancer biology on multiple levels.The company will host a key opinion leader ((KOL)) event this morning at 8:00 am ET

For further details see:

IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%